$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map

Safety Of CD47 Asset A Major Attraction?

 
• By Ian Haydock
CD47
CD47, The Subject Of Major New I-Mab/AbbVie Alliance • Source: Shutterstock

More from Immuno-oncology

More from Anticancer